Arvinas Inc. to Present Promising Preclinical Data for PROTAC BCL6 Degrader ARV-393 at 2025 EHA Annual Meeting
Arvinas Inc., a clinical-stage biotechnology company, has announced that it will present new preclinical data on ARV-393, an investigational oral PROTAC BCL6 degrader, at the European Hematology Association (EHA) Annual Meeting in Milan, Italy, from June 12-15, 2025. The data will highlight ARV-393's efficacy as a single agent in preclinical models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (AITL), transformed follicular lymphoma, and in combination with small molecule inhibitors in models of diffuse large B-cell lymphoma. The presentation is scheduled for June 13, 2025, from 6:30-7:30 p.m. CEST. Further details, including the full abstract, are available through the EHA 2025 online interactive program.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9463893-en) on June 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.